2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

2019 年印度全国预防肝脏共识研究协会更新 ，诊断,印度肝细胞癌的治疗 ： Puri II 建议。

• 发表时间: Jan-Feb 2020
• 来源期刊: J Clin Exp Hepatol
• DOI: 10.1016/j.jceh.2019.09.007
• PMID: 32025166
• 文章类型: Journal Article
• 作者列表: Kumar A,Acharya SK,Singh SP,Arora A,Dhiman RK,Aggarwal R,Anand AC,Bhangui P,Chawla YK,Datta Gupta S,Dixit VK,Duseja A,Kalra N,Kar P,Kulkarni SS,Kumar R,Kumar M,Madhavan R,Mohan Prasad VG,Mukund A,Nagral A,Panda D,Paul SB,Rao PN,Rela M,Sahu MK,Saraswat VA,Shah SR,Shalimar ,Sharma P,Taneja S,Wadhawan M,

关键词: AFP, alpha-fetoprotein; AIH, autoimmune hepatitis; ALT, alanine aminotransferase; DAA, direct-acting antiviral; DALY, disability-adjusted life-year; DNA, deoxyribonucleic acid; GRADE, Grading of Recommendations Assessment Development and Evaluation; Gd-BOPTA, gadolinium benzyloxypropionictetraacetate; Gd-EOB-DTPA, gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid; HBV, hepatitis B virus; HBeAg, hepatitis B envelope antigen; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; IARC, International Agency for Research on Cancer; IFN, interferon; INASL, Indian National Association for Study of the Liver; MiRNA, micro-RNA; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; PIVKA, protein induced by vitamin K absence; RFA; RNA, ribonucleic acid; SVR, sustained virological response; TACE; TACE, trans-arterial chemoembolization; TARE, transarterial radioembolization; TNF, tumor necrosis factor; WHO, World Health Organization; liver cancer; targeted therapy; transplant

Abstract

Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality, and healthcare expenditure in patients with chronic liver disease in India. The Indian National Association for Study of the Liver (INASL) had published its first guidelines on diagnosis and management of HCC (The Puri Recommendations) in 2014, and these guidelines were very well received by the healthcare community involved in diagnosis and management of HCC in India and neighboring countries. However, since 2014, many new developments have taken place in the field of HCC diagnosis and management, hence INASL endeavored to update its 2014 consensus guidelines. A new Task Force on HCC was constituted that reviewed the previous guidelines as well as the recent developments in various aspects of HCC that needed to be incorporated in the new guidelines. A 2-day round table discussion was held on 5th and 6th May 2018 at Puri, Odisha, to discuss, debate, and finalize the revised consensus statements. Each statement of the guideline was graded according to the Grading of Recommendations Assessment Development and Evaluation system with minor modifications. We present here the 2019 Update of INASL Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri-2 Recommendations.

摘要

肝细胞癌(HCC)是其发病的主要原因之一。死亡率,以及印度慢性肝病患者的医疗支出。印度全国肝脏研究协会（INASL）于2014年发布了有关HCC诊断和管理的第一份指南（PuriRecommendations），这些指南在印度和邻国的HCC诊断和管理中受到医疗保健界的好评。然而,自2014年以来，HCC诊断和管理领域出现了许多新的发展，因此，INASL努力更新其2014年共识指南。成立了一个新的HCC工作队，审查了以前的准则以及需要纳入新准则的HCC各个方面的最新发展。为期2天的圆桌讨论于2018年5月5日和6日在普里举行，奥里萨邦,讨论,辩论,并完成修订后的协商一致声明。指南的每个陈述都根据建议评估开发和评估系统的分级进行了分级，并进行了少量修改。我们在这里介绍2019年INASL预防共识更新，诊断,印度肝细胞癌的治疗：Puri-2建议。